<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793919</url>
  </required_header>
  <id_info>
    <org_study_id>ICC APL STUDY 02</org_study_id>
    <secondary_id>2017-002383-40</secondary_id>
    <nct_id>NCT04793919</nct_id>
  </id_info>
  <brief_title>Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia</brief_title>
  <official_title>Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associazione Italiana Ematologia Oncologia Pediatrica</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associazione Italiana Ematologia Oncologia Pediatrica</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who&#xD;
      are PCR-positive for the PML-RARα transcript and less than 18 years of age.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acute promyelocytic leukemia (APL) in children has become a highly curable disease with the&#xD;
      combination of all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy with an&#xD;
      overall remission rates equal to or higher than 98% and cure rates now exceeding 80% 1-9.&#xD;
&#xD;
      Based on data coming from adults indicating that at least standard-risk APL patients may be&#xD;
      cured without chemotherapy (i.e., with a treatment combining arsenic trioxide (ATO) and ATRA&#xD;
      only) 10-12, this ICC APL 02 study was designed with the aim of validating the efficacy of a&#xD;
      treatment combining:&#xD;
&#xD;
        -  ATO and ATRA in newly diagnosed APL standard-risk (SR) children and adolescents and&#xD;
&#xD;
        -  ATO, ATRA and gemtuzumab ozogamicin (GO) in newly diagnosed APL high-risk (HR) children&#xD;
           and adolescents.&#xD;
&#xD;
      Following one induction course of treatment combining ATO and ATRA +/- GO depending on risk&#xD;
      stratification, patients will receive 4 ATO/ATRA based consolidation blocks. This is the&#xD;
      first pediatric trial delivering a non-chemotherapy-based treatment for children with APL,&#xD;
      being the whole treatment based on the use of ATRA, ATO (and GO in HR patients). The aim of&#xD;
      the study is to demonstrate at least an equivalent efficacy and safety of this treatment not&#xD;
      containing cytostatic agents compared to the standard protocols combining ATRA and&#xD;
      chemotherapy (i.e. ICC APL Study 01).&#xD;
&#xD;
      The trial is open to all patients with a diagnosis of acute promyelocytic leukemia (APL) who&#xD;
      are PCR-positive for the PML-RARα transcript and less than 18 years of age.&#xD;
&#xD;
      This will be an international study, comprising the most important pediatric European groups,&#xD;
      expecting to recruit 46 and 43 patients in SR and HR arms, respectively, in 3 years. The&#xD;
      duration of study recruitment will be 36 months with a minimum follow-up per patient of 2&#xD;
      years.&#xD;
&#xD;
      The evaluation of morphological CR will be carried out after induction therapy, prior to the&#xD;
      first block of consolidation therapy. MRD results after induction will not have an impact on&#xD;
      subsequent therapy. By contrast, MRD results after the third consolidation course will&#xD;
      influence the subsequent treatment, MRD-positive patients being eligible to rescue treatment,&#xD;
      including hematopoietic stem cell transplantation (HSCT). BM aspirates will be repeated after&#xD;
      the end of therapy, and 3 months, 6 months, 9 months and 12 months after treatment&#xD;
      discontinuation.&#xD;
&#xD;
      This is a collaborative international study in APL in children and adolescents aimed at&#xD;
      providing information about procedures for the entry, treatment and follow-up of pediatric&#xD;
      patients with APL. It is not intended that this document be used as an aide-memoir or guide&#xD;
      for the treatment of other patients. Every care has been taken in its drafting, but&#xD;
      corrections and amendments may be necessary. Before entering patients into the study,&#xD;
      clinicians must ensure that the study has received clearance from their Local Research Ethics&#xD;
      Committee and any other necessary body.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 9, 2019</start_date>
  <completion_date type="Anticipated">October 10, 2024</completion_date>
  <primary_completion_date type="Anticipated">October 10, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS) probability</measure>
    <time_frame>3 years</time_frame>
    <description>SR patients: To evaluate the efficacy in terms of event-free survival of a treatment combining arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in newly diagnosed APL standard-risk children and adolescents HR patients: To evaluate the efficacy in terms of event-free survival of a treatment combining arsenic trioxide (ATO), all-trans retinoic acid (ATRA) and gemtuzumab ozogamicin (GO) in newly diagnosed APL high-risk children and adolescents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of hematological CR/CRi after induction</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the rate of hematological Complete Remission (CR) (defined as bone marrow regenerating normal hematopoietic cells and containing &lt; 5% blast cells by morphology, with ANC in peripheral blood &gt; 1.0 x 10^9/L and platelet count &gt; 100 x 10^9/L) and Complete Remission with incomplete hematologic recovery (CRi) (defined as CR except that peripheral blood neutrophils and/or platelets do not meet the criteria as defined above) after induction therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular CR/CRi after induction</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the rate of molecular CR/CRi (defined as the absence of PML/RARα fusion transcript in bone marrow assessed by RQ-PCR, with an assay sensitivity of at least 10^-4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of early death during induction</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the rate of early death during induction (defined as any death occurring within 14 days from diagnosis from any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Probability of overall survival (OS) at 3 years</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the rate of overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse (CIR) at 3 years</measure>
    <time_frame>3 years</time_frame>
    <description>To evaluate the cumulative incidence of hematological relapse (defined as reappearance of promyeloblasts/abnormal promyelocytes &gt; 5% in the bone marrow) and molecular relapse (defined as reappearance of PML/RARα fusion transcript in two successive samples taken at least 2 weeks apart in patients previously in molecular remission).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hematological and non-hematological toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Incidence of treatment-related hematological and non-hematological toxicity assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of molecular remission after 3 consolidation cycles</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the rate of molecular remission (defined as the absence of PML/RARα fusion transcript in bone marrow assessed by RQ-PCR, with an assay sensitivity of at least 10^-4) after 3 consolidation cycles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PML/RARα transcription level reduction during treatment</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the reduction of PML/RARα fusion transcript in bone marrow by means of RQ-PCR during treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pediatric Quality of Life assessment</measure>
    <time_frame>5 years</time_frame>
    <description>Pediatric Quality of life assessed by PedsQoL questionnaire, in the questionnaire there is a list of things that might be a problem for the child. The minimum value is 0 (never a problem) - maximum value 4 (almost always problem)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total hospitalization days during therapy</measure>
    <time_frame>5 years</time_frame>
    <description>Number of total hospitalization days during the treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">89</enrollment>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient with APL and WBC less than 10x10e9/L at presentation before start treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Risk (HR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with APL, with the highest pre-treatment WBC count equal to or greater than 10x10e9/L at presentation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mylotarg</intervention_name>
    <description>See the protocol</description>
    <arm_group_label>High Risk (HR)</arm_group_label>
    <other_name>GO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arsenic Trioxide</intervention_name>
    <description>See the protocol</description>
    <arm_group_label>High Risk (HR)</arm_group_label>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <other_name>ATO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>All-trans retinoic acid</intervention_name>
    <description>See the protocol</description>
    <arm_group_label>High Risk (HR)</arm_group_label>
    <arm_group_label>Standard Risk (SR)</arm_group_label>
    <other_name>ATRA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed APL confirmed by the presence of PML/RARα fusion gene&#xD;
&#xD;
          -  Age &lt;18 years&#xD;
&#xD;
          -  Written informed consent by parents or legal guardians&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a clinical diagnosis of APL but subsequently found to lack PML/RARα&#xD;
             rearrangement should be withdrawn from the study and treated on an alternative&#xD;
             protocol&#xD;
&#xD;
          -  Significant liver dysfunction (bilirubin serum levels &gt;3 mg/dL, ALT/AST serum levels&#xD;
             greater than 5 times the normal values)&#xD;
&#xD;
          -  Creatinine serum levels &gt;2 times the normal value for age&#xD;
&#xD;
          -  Significant arrhythmias, EKG abnormalities (*see below), other cardiac&#xD;
             contraindications (L-FEV &lt;50% or LV-FS &lt;28%)&#xD;
&#xD;
          -  Neuropathy&#xD;
&#xD;
          -  Concurrent active malignancy&#xD;
&#xD;
          -  Uncontrolled life-threatening infections&#xD;
&#xD;
          -  Pregnant or lactating female&#xD;
&#xD;
          -  Patients who had received alternative therapy (APL not initially suspected; ATRA&#xD;
             and/or ATO not available&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fanco Locatelli, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Pediatric Hematology Oncology - Bambino Gesù Children's Hospital Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AIEOP</last_name>
    <phone>0039 051 2144667</phone>
    <email>studiclinici@aieop.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Universitaire des Enfants Reine Fabiola (Huderf)</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laurence Dedeken, MD</last_name>
      <phone>+324772678</phone>
      <email>laurence.dedeken@huderf.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Motol</name>
      <address>
        <city>Praga</city>
        <zip>15006</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucie Sramkova, MD</last_name>
      <phone>22443 6401</phone>
      <phone_ext>+420</phone_ext>
      <email>lucie.sramkova@fnmotol.cz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatrics and Adolescent Medicine Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Henrik Hasle, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital des Enfants</name>
      <address>
        <city>Bordeaux-Cedex</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphane Ducassou, MD</last_name>
      <phone>0557820440</phone>
      <email>stephane.ducassou@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sophie REGUEME, MD</last_name>
      <phone>0557821067</phone>
      <email>sophie.regueme@chu-bordeaux.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen (AöR) Zentrum für Kinder-und Jugendmedizin Klinik für Kinderheilkunde III</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dirk Reinhardt, Prof</last_name>
      <phone>49-(0)201 1723-3784</phone>
      <email>Dirk.Reinhardt@uk-essen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Our Lady's Children's Hospital Crumlin</name>
      <address>
        <city>Dublin</city>
        <zip>12</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Owen P. Smith, Prof</last_name>
      <phone>003531-4096720</phone>
      <email>owen.smith@olchc.ie</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rappaport Children'S Hospital, Rambam Health Care Campus</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>NIRA ARAD-COHEN, MD</last_name>
      <phone>+972-50-206-1181</phone>
      <email>n_arad-cohen@rambam.health.gov.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale &quot;Casa Sollievo della Sofferenza&quot; - UO Oncoematologia Pediatrica</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Saverio Ladogana, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Dipartimento di Pediatria</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ospedale Papa Giovanni XXIII - USS Oncoematologia Pediatrica</name>
      <address>
        <city>Bergamo</city>
        <zip>24100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Massimo Provenzi, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Sant'Orsola-Malpighi - Oncologia ed Ematologia Pediatrica</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Pession, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Pediatrico Microcitemico &quot;A.Cau&quot;, Az.Ospedaliera Brotzu - SC Oncoematologia Ped. e Patologia della coagulazione</name>
      <address>
        <city>Cagliari</city>
        <zip>09121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosamaria Mura, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AOU Policlinico Vittorio Emanuele - UOC Ematologia ed Oncologia Pediatrica con TNO</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Lo Nigro, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Meyer - DAI Oncoematologia Pediatrica</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tommaso Casini, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Gannina Gaslini - Dipartimento di Oncoematologia</name>
      <address>
        <city>Genova</city>
        <zip>16147</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Micalizzi, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione Monza e Brianza per il Bambino e la sua Mamma (MBBM) - Ospedale San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmelo Rizzari, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>AORN Santobono-Pausilipon</name>
      <address>
        <city>Napoli</city>
        <zip>80123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giuseppe Menna, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Univerità degli Studi della Campania- Luigi Vanvitelli - Sevizio di Oncologia Pediatrica</name>
      <address>
        <city>Napoli</city>
        <zip>80138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Rossi, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova - Oncoematologia Pediatrica</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandra Biffi, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>ARNAS Civico di Cristina e Benfratelli - UOC Oncoematologia Pediatrica</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paolo D'Angelo, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo - Oncoematologia Pediatrica</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Zecca, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale santa Chiara - AOU Pisana, UO Oncoematologia Pediatrica</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gabriella Casazza, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I Università &quot;LA Sapienza&quot; - Dip. Biotecnologie cellulari ed ematologia UOS Ematologia Pediatrica</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anna Maria Testi, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Onco-Ematologia e Terapia Cellulare e Genica - Ospedale Pediatrico &quot;Bambino Gesù&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valentina Cirillo, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Franco Locatelli, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Franca Fagioli, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>VU medisch centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gertjan Kasper, Prof. dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Hospitalar Universitário de Coimbra - Hospital Pediátrico de Coimbra</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-602</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manuel Brito, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia de Lisboa Francisco Gentil, EPE</name>
      <address>
        <city>Lisbon</city>
        <zip>1099-023</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ximo Duarte, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia do Porto Francisco Gentil, E. P. E.</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vítor Costa, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Valencia University Medical School University Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miguel A. Sanz, MD</last_name>
      <email>domingo_joa@gva.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Childrens hematology and oncology Uppsala University</name>
      <address>
        <city>Uppsala</city>
        <zip>.O. Box 256, SE-751 05</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josefine Palle, MD</last_name>
      <email>josefine.palle@akademiska.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 13, 2019</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tretinoin</mesh_term>
    <mesh_term>Arsenic Trioxide</mesh_term>
    <mesh_term>Gemtuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

